Eyenovia, SGN Nanopharma to develop treatment for dry eye disease
Eyenovia and SGN Nanopharma have announced a collaboration agreement to develop a new drug-device combination product for chronic dry eye disease.
According to an Eyenovia press release, the agreement states that both companies will work to develop SGN’s Micellar Nanoparticle Platform (MNP) cyclosporine formulation to be used with Eyenovia’s Optejet dispenser. The companies are validating the product’s manufacturability to support clinical testing and will consult with the FDA on clinical development.
“We believe the power of SGN’s MNP platform, when combined with the Optejet, will result in a more efficacious and better tolerated cyclosporine-based treatment that we believe has the potential to become the standard of care in this multibillion-dollar addressable market,” Michael Rowe, Eyenovia’s CEO, said in the release.
Read more about